openPR Logo
Press release

GM1 Gangliosidosis Treatment Market

11-14-2023 08:37 AM CET | Health & Medicine

Press release from: DataM Intelligence 4market Research LLP

GM1 Gangliosidosis Treatment Market Size, Share, Industry, Forecast and Outlook (2023-2030)

GM1 Gangliosidosis Treatment Market Size, Share, Industry, Forecast and Outlook (2023-2030)

The GM1 Gangliosidosis Treatment Market is expected to witness substantial growth during the forecast period of 2023-2030. Here's an overview of the dynamics, segment analysis, geographical share, and impact of COVID-19 and the Russia-Ukraine war:

Market Overview:
The global GM1 gangliosidosis treatment market is anticipated to experience significant growth due to factors such as rising lysosomal storage disorders, increased research and development activities, and government investments in pharmaceuticals and biotechnology.

Market Dynamics:
Drivers:
Government Investments and Research: Increasing emphasis on GM1 gangliosidosis treatment through government investments in developing economies is driving the adoption of gene therapy and enhancing the market's growth.
Advancements in Clinical Outcomes: Positive outcomes from clinical trials and advancements in treatment methodologies are contributing to the market's expansion.

Challenges:
Limitations in Therapies: Limitations related to therapies, such as the challenges associated with gene therapy and the limitations of glucosylceramide synthase inhibition, pose challenges in treating GM1 gangliosidosis effectively.

Request for Sample: https://www.datamintelligence.com/download-sample/gm1-gangliosidosis-treatment-market

Segmentation Analysis:
Market Segments: The GM1 gangliosidosis treatment market is segmented based on type, treatment, end-user, and region, with gene therapy showing promising advantages for treatment.

Geographical Share:
North America: Dominates the market, particularly the United States, due to the region's strong presence of major players, increasing healthcare infrastructure investment, and research studies in GM1 gangliosidosis treatment.

COVID-19 Impact:
Supply Chain Disruptions: The COVID-19 pandemic caused significant disruptions in the medical device sector, impacting the demand for GM1 gangliosidosis treatment. Pharmaceutical plants reduced or suspended production due to decreased demand and supply chain disruptions.

Labor Shortages and Safety Measures: Labor shortages and stringent safety measures in pharmaceutical plants led to reduced workforce on-site, impacting crucial activities throughout the pandemic.

Russia-Ukraine War Impact:
The conflict has disrupted clinical trials and therapeutic developments, potentially leading to delays, loss of business continuity, and compliance issues for therapies already in the market. The shift of clinical trials from affected regions to other parts of Europe is being considered.

Key Developments:
Companies like Passage Bio, Lysogene, Sio Gene Therapies, Inc., among others, have released promising safety, biomarker, and clinical development data from their respective clinical trials, showcasing advancements in GM1 gangliosidosis treatment.

Key Companies:
Major players in the GM1 gangliosidosis treatment market include Passage Bio, Lysogene, Sio Gene Therapies, Inc., BioStrategies LC, Sanofi, AZAFAROS, Dorphan S.A., Idorsia Pharmaceuticals Ltd, SphinCS GmbH, and Viatris Inc.

The market for GM1 gangliosidosis treatment continues to evolve with promising advancements in gene therapy and ongoing research and development. However, challenges related to therapeutic limitations and external factors such as the COVID-19 pandemic and geopolitical disruptions pose significant hurdles for the market's growth and stability.

Related Reports:

https://www.datamintelligence.com/download-sample/alpha-mannosidosis-treatment-market
https://www.datamintelligence.com/download-sample/alpha-mannosidosis-treatment-market
https://www.datamintelligence.com/download-sample/mastocytosis-treatment-market

Media Contact
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com/

About DataM Intelligence
DataM Intelligence 4Market Research is a Market Research firm that provides end-to-end business solutions to organizations from Research to Consulting. We at DataM Intelligence leverage our top trademark trends, insights, and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of Syndicate Reports & and; Customized Reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries, catering to the key business research needs that influence the growth trajectory of our vast clientele

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release GM1 Gangliosidosis Treatment Market here

News-ID: 3286490 • Views:

More Releases from DataM Intelligence 4market Research LLP

Impact Resistant Glass Market Rises on Procurement Demand as security, mobility and infrastructure buyers upgrade transparent protection systems
Impact Resistant Glass Market Rises on Procurement Demand as security, mobility …
The Impact Resistant Glass Market was valued at USD 31.78 billion in 2025 and is expected to reach USD 53.78 billion by 2033, growing at a CAGR of 6.80% during the forecast period 2026-2033, according to DataM Intelligence. The market is increasingly connected to procurement decisions as security, mobility and infrastructure buyers seek transparent protection systems that combine visibility with impact resistance, safety and asset protection. Demand is being shaped
Ultraviolet Curing System Market Moves From Optional Upgrade to Operating Priority as manufacturers seek faster curing, lower solvent use and higher throughput surface finishing
Ultraviolet Curing System Market Moves From Optional Upgrade to Operating Priori …
The global Ultraviolet (UV) Curing System Market reached USD 5.37 billion in 2025 and is expected to reach USD 12.50 billion by 2033, growing at a CAGR of 10.1% during the forecast period 2026-2033. The market covers Mercury Lamps and UV LEDs by technology; Spot Cure, Flood Cure and Focused Beam, and Conveyor by type; High, Medium and Low by pressure; and applications including Printing, Bonding and Assembling, Coating and
Marine Mining Market Rises on Procurement Demand as seabed resource exploration triggers demand for specialized equipment, mapping and environmental safeguards
Marine Mining Market Rises on Procurement Demand as seabed resource exploration …
The global marine mining market was valued at USD 89.12 billion by 2035, expanding at a CAGR of 34.5% during 2026-2035, according to DataM Intelligence. The market is segmented by Technology into Marine Seismic Methods, Remotely Operated Vehicles (ROVs), and SONAR; by Application into Construction, Electronics, and Precious Metals; and by Region into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. As seabed resource exploration advances, procurement
Fruit Sorting Machinery Market Rises on Procurement Demand as fresh produce exporters use optical sorting to protect quality, yield and retailer compliance
Fruit Sorting Machinery Market Rises on Procurement Demand as fresh produce expo …
The global Fruit Sorting Machinery Market was valued at US$354.17 million in 2025 and is projected to reach US$576.91 million by 2035, expanding at a 5.0% CAGR during 2026-2035, according to DataM Intelligence. The market is increasingly tied to procurement decisions across fresh produce supply chains as exporters seek optical sorting and automated grading capabilities that can improve consistency, recover saleable yield, reduce quality related losses and support retailer and

All 5 Releases


More Releases for GM1

GM1 Gangliosidosis Market Research Explores Growth Within A $0.95 Billion Opport …
The GM1 gangliosidosis market is gaining significant momentum as advances in gene therapy and rare disease treatments continue to evolve. With growing investment and innovation, the landscape for managing this rare genetic disorder is expected to expand considerably over the coming years. Below is an in-depth look at the market's size projections, key players, emerging trends, and segmentation details that illustrate its current and future outlook. Projected Growth and Market Size
GM1 Gangliosidosis Treatment Market (2026) | GM1 Gangliosidosis Type 2 (Juvenile …
DataM Intelligence has released a new research report titled "GM1 Gangliosidosis Treatment Market Size 2026" The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in
GM1 Gangliosidosis Market Expected to Reach USD 1.6 Billion by 2034
GM1 gangliosidosis is a rare, inherited lysosomal storage disorder caused by mutations in the GLB1 gene, leading to a deficiency of the β-galactosidase enzyme. This results in the accumulation of GM1 gangliosides in cells, primarily affecting the central nervous system. The disease is classified into infantile, juvenile, and adult-onset forms, with infantile GM1 being the most severe and often fatal in early childhood. Download Full PDF Sample Copy of Market Report
GM1 Gangliosidosis Market Massive Growth opportunity Ahead
GM1 Gangliosidosis Market Outlook 2024-2034: Expanding Research, Orphan Drug Approvals, and Regional Growth Introduction GM1 Gangliosidosis is an ultra-rare, inherited lysosomal storage disorder caused by mutations in the GLB1 gene, leading to progressive neurodegeneration. Patients experience a range of symptoms-from developmental delays and skeletal abnormalities to severe motor dysfunction and premature mortality. With no approved curative therapy to date, treatment options remain largely supportive. However, the last decade has witnessed a surge in
GM1 Gangliosidosis Market Size And Global Industry Forecast 2034
Introduction The GM1 Gangliosidosis Market is gaining attention as advancements in genetic research and rare disease drug development open new possibilities for this ultra-rare lysosomal storage disorder. GM1 gangliosidosis is caused by mutations in the GLB1 gene, leading to a deficiency of the β-galactosidase enzyme and progressive neurodegeneration. With no approved curative treatments currently available, ongoing innovation in gene therapy, enzyme replacement therapy (ERT), and small molecule chaperones is fueling significant
GM1 Gangliosidosis Treatment Market Higher Mortality Rates by 2027
"Industry analysis is a crucial step in the current competitive market space that helps identify the right target customers and accordingly provide tailored solutions for their business needs. Every aspect and unique challenges put up by the particular industry are carefully taken into consideration while formulating these solutions. It also takes into consideration various government reforms, competitive environment, customer behavior, existing and upcoming business models, and ever-evolving technological developments. Industry